Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5627-5634

  Arrieta, Oscar ^a,b   Villarreal Garza, Cynthia ^a,c   Vizcaíno, Gloria ^a   Pineda, Benjamín ^d   Hernández Pedro, Norma ^a   Guevara Salazar, Patricia ^d   Wegman Ostrosky, Talia ^a   Villanueva Rodríguez, Geraldine ^a   Gamboa Domínguez, Armando ^e  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^d NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Angiogenesis; Angiotensin II; AT1 blockers; ATI; ATII; Breast cancer

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MITOSIS INDEX; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; VERY ELDERLY; BIOSYNTHESIS; BREAST NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2;

EID: 84938213886     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3235-3     Document Type: Article

References (46)

1. Jemal ABF, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Duchnowska R, Jassem J, Goswami CP, Dundar M, Gokmen-Polar Y, Li L, et al. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J Neuro-Oncol. 2015. doi:10.1007/s11060-014-1704-y.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. doi:10.1056/NEJM200103153441101.
4. Cianfrocca M. Overcoming recurrence risk: extended adjuvant endocrine therapy. Clin Breast Cancer. 2008;8(6):493–500. doi:10.3816/CBC.2008.n.059.
5. de Paepe B, Verstraeten VL, de Potter CR, Vakaet LA, Bullock GR. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol. 2001;116(3):247–54. doi:10.1007/s004180100313.
6. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70–88.
7. Vinson GP, Barker S, Puddefoot JR. The renin-angiotensin system in the breast and breast cancer. Endocr Relat Cancer. 2012;19(1):R1–19. doi:10.1530/ERC-11-0335.
8. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001;495(3):197–200.
9. Goldfarb DA, Diz DI, Tubbs RR, Ferrario CM, Novick AC. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol. 1994;151(1):208–13.
10. Batra VK, Gopalakrishnan V, McNeill JR, Hickie RA. Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors. Cancer Lett. 1994;76(1):19–24.
11. Arrieta O, Pineda-Olvera B, Guevara-Salazar P, Hernandez-Pedro N, Morales-Espinosa D, Ceron-Lizarraga TL, et al. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer. 2008;99(1):160–6. doi:10.1038/sj.bjc.6604431.
12. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29(9):1675–84. doi:10.1093/carcin/bgn171.
13. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16(7):293–9. doi:10.1016/j.tem.2005.07.009.
14. Tahmasebi M, Barker S, Puddefoot JR, Vinson GP. Localisation of renin-angiotensin system (RAS) components in breast. Br J Cancer. 2006;95(1):67–74. doi:10.1038/sj.bjc.6603213.
15. Tybitanclova K, Macejova D, Liska J, Brtko J, Zorad S. AT1 receptor and ACE mRNA are increased in chemically induced carcinoma of rat mammary gland. Mol Cell Endocrinol. 2005;244(1–2):42–6. doi:10.1016/j.mce.2005.01.015.
16. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis. 2005;26(2):271–9. doi:10.1093/carcin/bgh324.
17. Jethon A, Pula B, Piotrowska A, Wojnar A, Rys J, Dziegiel P, et al. Angiotensin II type 1 receptor (AT-1R) expression correlates with VEGF-A and VEGF-D expression in invasive ductal breast cancer. Pathol Oncol Res. 2012;18(4):867–73. doi:10.1007/s12253-012-9516-x.
18. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009;106(25):10284–9. doi:10.1073/pnas.0900351106.
19. de Paepe B, Verstraeten VM, de Potter CR, Bullock GR. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol. 2002;117(1):13–9. doi:10.1007/s00418-001-0356-0.
20. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20(17):3628–36.
21. Howell LP, Gandour-Edwards R, O’Sullivan D. Application of the Scarff-Bloom-Richardson tumor grading system to fine-needle aspirates of the breast. Am J Clin Pathol. 1994;101(3):262–5.
22. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer. 2006;94(4):552–60. doi:10.1038/sj.bjc.6602961.
23. Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol. 2001;158(5):1633–7. doi:10.1016/S0002-9440(10)64119-3.
24. Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002;94(12):3210–8. doi:10.1002/cncr.10594.
25. Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Perez R, Arrieta O. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res. 2005;24(4):575–83.
26. Kosugi M, Miyajima A, Kikuchi E, Kosaka T, Horiguchi Y, Murai M. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum Cell. 2007;20(1):1–9. doi:10.1111/j.1749-0774.2007.00025.x.
27. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millan S, Sanchez-Corona J. The renin-angiotensin system meets the hallmarks of cancer. J Renin-Angiotensin-Aldosterone Syst. 2013. doi:10.1177/1470320313496858.
28. Azizi M. Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists. La Revue du Praticien. 2004;54(11):1167–74.
29. Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, et al. Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One. 2012;7(4):e35667. doi:10.1371/journal.pone.0035667.
30. Wang L, Cai SR, Zhang CH, He YL, Zhan WH, Wu H, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin Med J. 2008;121(21):2167–71.
31. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(7):2686–94. doi:10.1158/1078-0432.CCR-04-1946.
32. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol. 2004;2(4):385–99.
33. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem. 2004;279(28):28989–97. doi:10.1074/jbc.M403880200.
34. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2(11):1139–47.
35. Wruck CJ, Funke-Kaiser H, Pufe T, Kusserow H, Menk M, Schefe JH, et al. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol. 2005;25(1):57–64. doi:10.1161/01.ATV.0000150662.51436.14.
36. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, et al. Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol. 2008;109(3):418–25. doi:10.1016/j.ygyno.2008.02.019.
37. Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 2013;328(2):318–24. doi:10.1016/j.canlet.2012.10.006.
38. Puddefoot JR, Udeozo UK, Barker S, Vinson GP. The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocr Relat Cancer. 2006;13(3):895–903. doi:10.1677/erc.1.01136.
39. Zhao Y, Wang H, Li X, Cao M, Lu H, Meng Q, et al. Ang II-AT1R increases cell migration through PI3K/AKT and NF-kappaB pathways in breast cancer. J Cell Physiol. 2014;229(11):1855–62. doi:10.1002/jcp.24639.
40. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol. 2003;196(2):370–7. doi:10.1002/jcp.10313.
41. Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmacol Ther. 2011;130(2):177–90. doi:10.1016/j.pharmthera.2011.01.009.
42. Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012;23(2):221–30. doi:10.1007/s10552-011-9881-x.
43. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Investig. 2011;29(9):585–93. doi:10.3109/07357907.2011.616252.
44. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129(2):549–56. doi:10.1007/s10549-011-1505-3.
45. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer. 2013;4(7):549–56. doi:10.7150/jca.6888.
46. Redondo-Muller MA, Stevanovic-Walker M, Barker S, Puddefoot JR, Vinson GP. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr Relat Cancer. 2008;15(1):277–88. doi:10.1677/ERC-07-0068.